PCN44 Cost-Effectiveness of Durvalumab Following Chemoradiotherapy in Unresectable Stage III NSCLC Patients in the US: An Update Based on 4-Year Survival Data
Abstract
Authors
B. Seal M.J. Mooradian M. Van Keep W. Dunlop L. Brannman C. Yong